Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of Multiple Rising Oral Doses of Avenciguat in Healthy Males
NCT03116906Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2017
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in diabetic kidney disease (DKD), Liver cirrhosis (LC), Portal Hypertension (PH) and 1 more comparing BI 685509 with Placebo (2 arms). Primary endpoint: Percentage of subjects with drug-related Adverse Events at 5 weeks. Started Apr 2017; status: completed.
02
Drugs
avenciguat
03
Conditions
diabetic kidney disease (DKD)Liver cirrhosis (LC)Portal Hypertension (PH)systemic sclerosis (SSc)
Beyond the preview
Go deeper on NCT03116906.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03116906.